Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Eli Lilly Stock Plummets As Zepbound, Mounjaro Sales Miss Estimates
Eli Lilly stock fell sharply after the drug maker posted quarterly earnings that missed analysts’ expectations. The company reported adjusted earnings of $1.18 a share on revenue of $11.44 billion, compared to analysts’ estimates for earnings of $1.
Lilly Hit With Lower-Than-Expected Mounjaro and Zepbound Q3 Sales, Narrows Full-Year Forecast
Eli Lilly’s blockbuster weight loss and diabetes drugs missed analysts’ expectations by 18% in the third quarter, which were negatively impacted by inventory stocking in the wholesaler channel. The company’s shares fell more than 13% in trading on Wednesday morning.
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the consensus estimates.
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook observed through 1H24. Read more here.
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by wholesale distributors hurt sales of its diabetes drug Mounjaro and anti-obesity medicine Zepbound.
Eli Lilly’s stock tumbles as Mounjaro, Zepbound sales miss expectations by wide margins
Shares of Eli Lilly and Co. tumbled 9.6% in premarket trading Wednesday, after the drug maker reported third-quarter profit and revenue that missed expectations by wide margins, as sales of obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...
Ibj.com12h
UPDATE: Lilly shares tumble on earnings report that falls short of Wall Street expectations
The Indianapolis-based drugmaker missed expectations on sales of two popular drugs, diabetes treatment Mounjaro and ...
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections
As weight-loss injections emerge as key players in the government’s anti-obesity strategy, Emma Loffhagen goes inside the ...
Zepbound, Mounjaro Maker Eli Lilly Climbs In Wednesday Pre-Market As Impressive 51% YTD Gain Sparks Stock Split Speculation
Eli Lilly And Co (NYSE:LLY) experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick ...
Inverness Courier2d
Over £200-a-month - the cost of living with type 2 diabetes for an Inverness gran
An Inverness woman is paying more than £200-a-month for medication to treat her Type 2 diabetes because doctors have told her ...